Obesity is a risk factor for many diseases including diabetes, cardiovascular disease and cancer. With 50% of the population predicted to be obese by 2030, obesity is a major public health problem. There are few effective management strategies in the treatment of obesity and even fewer pharmacological therapies. At present, the only licensed drug therapy in the UK is orlistat. A centrally acting anti-obesity agent comprised of prolonged release naltrexone and bupropion (NB) is available in the US and may soon be licensed in the UK.
展开▼
